|
Recently, a novel antimicrobial peptide including Buforin II has been emphasized to kill multi-drug resistant bacteria and avoid promoting multi-drug resistance. This study evaluated the efficacy of an antimicrobial peptide (Buforin IIb) on bovine mastitis. Based on the Minimum inhibitory concentration(MIC, 4 g/ml) of Buforin IIb, syringes were made five concentration(MIC×10, ×50, ×100, ×300, and ×500). Thirty three cows(38 quarters) with bovine mastitis were selected using California mastitis test and grouped in dependant on drug concentration and treatment duration. Each group treated by intramammary infusion twice a day for 3 5 days. The milk samples of 5 groups were aseptically collected from quarters at 0, 3, 7 and 14 days, and 2 groups were collected at 0, 5, 9 and 14 days after first treatment. Collected samples were used for bacterial culture and somatic cell count. Bacterial number(log_(10) mean CFU/ml) was decreased in dependant on drug concentration and extending treatment duration. In group D(MIC×300), bacterial number was decreased from 4.59±0.10(day 0) to 2.89±1.37(day 3), 4.04±0.33(day 7), and 4.19 ± 0.10(day 14), respectively(p 0.05). Bacterial number of B2(MIC×50, 5 days treated) is decreased, approximately 10%, than group B1(MIC×50, 3 days treated). Somatic cell count of group D was slightly decreased from 11,100(×10³)(day 0), to 7,386(×10³)(3 day), 6,886(×10³)(day 7), and 9,661(×10³)(day 14). Staphylococcus spp., was the most common isolate, was bacteriologically cured 100% by Buforin IIb treatment. Overall results indicate that Buforin IIb could have possibility to cure bovine mastitis, if higher concentration over experimental concentration were treated with extending treatment duration.
|